Back to search results

DSLT for Reducing Glaucoma Medication

This study is looking at whether a laser treatment called Voyager DSLT (Direct Selective Laser Trabeculoplasty) can help people with ocular hypertension (high eye pressure) or primary open angle glaucoma reduce the number of eye drops they need. You might be able to join if you have one of these conditions, are an adult, and are currently using 1 to 3 eye drop medications to control your eye pressure. The study will measure if you need fewer medications after 6 months. It's an observational study, meaning researchers will watch what happens after the treatment, and plans to include 60 participants.

Study design
This is an observational, single-site study that will follow 60 participants. It is an open-label study, meaning both you and the researchers will know you are receiving the DSLT treatment.
What's involved
Participants will undergo DSLT treatment, which involves 120 laser shots to the eye. The study will then assess your medication use at 6 months after the treatment.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after the DSLT treatment to assess medication reduction and other outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07390890

DSLT for Reducing Medication in Glaucoma

Recruiting
Not specifiedAll AgesObservational
The Eye Institute of West Florida
~60 participants
Updated 2026-04-20 on ClinicalTrials.gov
What's tested:Voyager DSLT

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP)
Measured over 6 months post-DSLT treatment

Conditions

Primary Open Angle Glaucoma
Ocular Hypertension

Explore related trials

Ocular HypertensionPrimary Open Angle Glaucoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Neel Desai, MD · PRINCIPAL_INVESTIGATOR · The Eye Institute of West Florida

Who to contact

Renee Bondurant
[email protected]
727-450-4668
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients scheduled to undergo DSLT treatment in one or both eyes.
Diagnosis of ocular hypertension or primary open angle glaucoma (POAG).
Medically controlled on 1-3 topical ocular hypotensive agents with IOP ≤21 mmHg.

Exclusion

Previous glaucoma surgeries/interventions:
Patients who have undergone prior glaucoma-related procedures (e.g., trabeculectomy, laser trabeculoplasty, MIGS, or tube shunt).
Patients who have undergone cataract surgery within the prior 2 years.
Secondary glaucoma:
Patients with secondary forms of glaucoma, such as angle-closure glaucoma, neovascular glaucoma, or glaucoma resulting from trauma or other systemic diseases.
Other significant ocular conditions including advanced cataracts, retinal diseases (e.g., age-related macular degeneration), or any condition that might complicate the assessment of intraocular pressure (IOP) or visual function as deemed by the investigator.

What this trial measures

  • Reduction in the number of glaucoma medications required to maintain target intraocular pressure (IOP)6 months post-DSLT treatment

    The primary outcome will be assessed by comparing the number of medications needed to maintain target IOP before and after DSLT treatment.